Physician profile
John D Gover
NPI 1467450635
$9,715.52
in general payments reported to CMS, 2019-2025
55 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $651 · 2021: $920 · 2022: $1,271 · 2023: $1,874 · 2024: $1,908 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,835 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,835.10 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.69 | 2019-2025 | |
| Pfizer INC. | $873.22 | 2019-2025 | |
| Amgen INC. | $841.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $747.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $701.78 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $673.11 | 2019-2025 | |
| Lilly USA, LLC | $433.20 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $431.77 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.48 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $269.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $253.99 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $235.15 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $207.72 | 2019-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $193.42 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.27 | 2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.